June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Corneal graft rejection was prevented by conbercept eye drop in vascularized cornea
Author Affiliations & Notes
  • Hongshan Liu
    Corneal and External Disease, Hainan Eye Hospital, Haikou, China
  • Xingwu Zhong
    Corneal and External Disease, Hainan Eye Hospital, Haikou, China
  • Footnotes
    Commercial Relationships Hongshan Liu, None; Xingwu Zhong, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4511. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hongshan Liu, Xingwu Zhong; Corneal graft rejection was prevented by conbercept eye drop in vascularized cornea. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4511.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Corneal neovascularization is a distinctive sign of immune privilege crash of cornea, which is the main incentive to induce the graft rejection after corneal transplantation. To avoid the graft rejection after corneal transplantation of alkali burned cornea, conbercept eye drop was used to prevent the graft rejection following corneal transplantation.

Methods: The cornea of New Zealand rabbits was burned by placing a Whatman filter paper (8.00 mm in diameter) soaked in 1 N NaOH onto the cornea for 60 seconds followed by washing with PBS for 60 seconds and allowed the injured cornea to heal for 20 days prior to corneal transplantation using a donor cornea collected from Angola rabbit. After surgery, conbercept eye drop was applied to prevent the immune graft rejection and FK-506 eye drop was used as the control. Immunostaining was employed to label the neovascular vessels, inflammatory cells, and lymphatic vessels with the antibody of anti-CD31, vEGF, CD45, CD11b, lyve1, etc.

Results: After corneal alkali burn, central cornea changed to be cloudy and central corneal epithelium was broken; 2 weeks later, blood vessels proliferated to central cornea from limbus. Following corneal transplantation and application of eye drops, corneal blood vessels were significantly suppressed by treatment of conbercept eye drop and cornea was kept to be transparent; however, the corneas treated by FK-506 eye drop were vascularized and only 3 in 10 corneas were transparent 10 weeks after the treatment. Histology revealed that very few inflammatory cells were found in the corneas treated by conbercept eye drop in comparison with that of FK-506 eye drop at 10 week after corneal transplantation. Moreover, the expression of CD31 and vEGF was significantly reduced in the cornea treated with conbercept eye drop, which revealed by Western blot.

Conclusions: Application of conbercept eye drop may be a valuable treatment to prevent corneal graft rejection through the suppression of corneal neovascularization.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.